Xacduro: Dosage Form, Projected Sales, NCE-1 Date | Sulbactam, Durlobactam

Xacduro

Xacduro is an IV antibiotic used for serious lung infections caused by resistant Acinetobacter bacteria. It combines two medicines to fight tough infections effectively.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Sulbactam And Durlobactam
Innovator :

ENTASIS THERAPEUTICS INC
Approval Date :

23-May-23
NCE-1 Date :

23-May-27
NCE Date :

23-May-28
Dosage Form :

IV Injection
Strength :

EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL
Therapeutic Category :

Antibiotic
Revenue ($M) :

24

Year-wise Projected Sales ($M) :

2025 :

51
2026 :

109
2027 :

186
2028 :

258
2029 :

334
2030 :

382
2031 :

438

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Xacduro

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?